This thesis presents an economic analysis of factors influencing HTA drug funding decision-making for "high-cost" cancer drugs. Four research questions are considered. Literature review identifies the factors prioritized by payers, public and patients in funding decision-making for new cancer drugs. An empirical analysis then identifies the factors prioritized by Scotland in decision-making. The third empirical analysis applies survival analysis to identifies factors which increase or decrease time to a positive recommendation. The final analyses test if uptake of Risk Sharing Agreements significantly increases access to publicly-funded cancer drugs, and identifies the conditions which facilitate a Risk-sharing agreement.
Principal supervisorAnthony Harris
Additional supervisor 1Jeff Richardson
Year of Award2018
Department, School or CentreCentre for Health Economics
Additional Institution or OrganisationCenter for Health Economics
CourseDoctor of Philosophy
FacultyFaculty of Business and Economics